NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free ORGS Stock Alerts $0.52 +0.01 (+1.96%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.50▼$0.5250-Day Range$0.34▼$0.9052-Week Range$0.25▼$1.50Volume18,325 shsAverage Volume419,631 shsMarket Capitalization$17.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Orgenesis alerts: Email Address Orgenesis MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.87% of Shares Sold ShortDividend StrengthN/ASustainability-1.49Upright™ Environmental ScoreNews Sentiment0.32Based on 2 Articles This WeekInsider TradingAcquiring Shares$19,583 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 starsMedical Sector647th out of 909 stocksPharmaceutical Preparations Industry293rd out of 425 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Orgenesis. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.87% of the outstanding shares of Orgenesis have been sold short.Short Interest Ratio / Days to CoverOrgenesis has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orgenesis has recently decreased by 6.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOrgenesis does not currently pay a dividend.Dividend GrowthOrgenesis does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOrgenesis has received a 66.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Gene therapy medication", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Orgenesis is -1.49. Previous Next 2.4 News and Social Media Coverage News SentimentOrgenesis has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Orgenesis this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ORGS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows2 people have added Orgenesis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orgenesis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,583.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.14% of the stock of Orgenesis is held by insiders.Percentage Held by InstitutionsOnly 22.56% of the stock of Orgenesis is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Orgenesis is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orgenesis is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About Orgenesis Stock (NASDAQ:ORGS)Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.Read More ORGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORGS Stock News HeadlinesApril 17, 2024 | investing.comOrgenesis secures $2.3 million investment and strategic partnershipApril 17, 2024 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Year End Business UpdateApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 15, 2024 | globenewswire.comOrgenesis Provides Year End Business UpdateApril 11, 2024 | investing.comGermfree partners with Orgenesis to enhance CGT productionApril 10, 2024 | globenewswire.comGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityMarch 18, 2024 | globenewswire.comVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceMarch 13, 2024 | globenewswire.comOrgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.March 4, 2024 | globenewswire.comOrgenesis Inc. Announces $2.3 Million Private PlacementFebruary 29, 2024 | globenewswire.comOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingFebruary 23, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS)February 22, 2024 | morningstar.comOrgenesis Inc ORGSJanuary 31, 2024 | msn.comEXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To ClinicJanuary 31, 2024 | finance.yahoo.comOrgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicJanuary 8, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo FinanceNovember 22, 2023 | finance.yahoo.comAnalysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven SoonNovember 15, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comOrgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMNovember 13, 2023 | finance.yahoo.comOrgenesis Provides Business Update for the Third Quarter of 2023November 8, 2023 | finance.yahoo.comOrgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingNovember 5, 2023 | forbes.com6 Secrets Of Organizations That Successfully Adapt To ChangeNovember 2, 2023 | finance.yahoo.comOrgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingOctober 31, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Announces Withdrawal of Proposed Public OfferingOctober 30, 2023 | finance.yahoo.comOrgenesis Announces Withdrawal of Proposed Public OfferingOctober 30, 2023 | finance.yahoo.comOrgenesis Announces Proposed Underwritten Public OfferingSeptember 21, 2023 | stockhouse.comCGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United StatesSee More Headlines Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORGS CUSIPN/A CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees167Year Founded2008Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,360,000.00 Net Margins-91.25% Pretax Margin-12,159.43% Return on Equity-590.97% Return on Assets-126.17% Debt Debt-to-Equity Ratio1.48 Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual Sales$530,000.00 Price / Sales33.63 Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-0.79Miscellaneous Outstanding Shares34,340,000Free Float31,887,000Market Cap$17.82 million OptionableOptionable Beta1.07 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Vered Caplan M.Sc. (Age 55)Chairperson of the Board, CEO & President Comp: $335.97kProf. Sarah Ferber Ph.D. (Age 70)Founder & Chief Scientific Officer Comp: $268.32kMr. Victor Miller (Age 54)Chief Financial Officer Pierre LammeretzInterim Chief Operating OfficerDr. Shimon Hassin Ph.D.Chief Technology OfficerMr. Evan FishmanChief Financial Officer of Orgenesis BiotechMr. Joseph CarpinelliChief Financial Officer of OctomeraMore ExecutivesKey CompetitorsBenitec BiopharmaNASDAQ:BNTCMinerva NeurosciencesNASDAQ:NERVFSD PharmaNASDAQ:HUGEKALA BIONASDAQ:KALAVBI VaccinesNASDAQ:VBIVView All CompetitorsInsidersJacob SafierBought 10,100 shares on 2/1/2024Total: $3,333.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/30/2024Total: $8,250.00 ($0.33/share)Jacob SafierBought 25,000 shares on 1/25/2024Total: $8,000.00 ($0.32/share)Jacob SafierBought 10,000 shares on 1/22/2024Total: $2,900.00 ($0.29/share)Jacob SafierBought 10,000 shares on 1/18/2024Total: $3,300.00 ($0.33/share)View All Insider Transactions ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed in 2024? Orgenesis' stock was trading at $0.5007 on January 1st, 2024. Since then, ORGS stock has increased by 3.7% and is now trading at $0.5190. View the best growth stocks for 2024 here. When is Orgenesis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ORGS earnings forecast. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) released its quarterly earnings data on Friday, August, 11th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.06 by $0.21. The business had revenue of $6.98 million for the quarter. Orgenesis had a negative trailing twelve-month return on equity of 590.97% and a negative net margin of 91.25%. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Orgenesis have any subsidiaries? The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.Read More This page (NASDAQ:ORGS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
